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Individual Patient Data Subgroup Meta-Analysis of Surgery
for Spontaneous Supratentorial Intracerebral Hemorrhage
Barbara A. Gregson, PhD; Joseph P. Broderick, MD; Ludwig M. Auer, MD; Hunt Batjer, MD;
Xian-Cheng Chen, MD; Seppo Juvela, MD; Lewis B. Morgenstern, MD; George C. Pantazis, MD;
Onno P.M. Teernstra, PhD; Wen-Zhi Wang, MD; Mario Zuccarello, MD; A. David Mendelow, FRCS
Background and Purpose—By 2010 there had been 14 published trials of surgery for intracerebral hemorrhage reported
in systematic reviews or to the authors, but the role and timing of operative intervention remain controversial and the
practice continues to be haphazard. This study attempted to obtain individual patient data from each of the 13 studies
published since 1985 to better define groups of patients that might benefit from surgery.
Methods—Authors of identified published articles were approached by mail, e-mail, and at conferences and invited to take
part in the study. Data were obtained from 8 studies (2186 cases). Individual patient data included patient’s age,
Glasgow Coma Score at presentation, volume and site of hematoma, presence of intraventricular hemorrhage, method
of evacuation, time to randomization, and outcome.
Results—Meta-analysis indicated that there was improved outcome with surgery if it was undertaken within 8 hours of
ictus (P0.003), or the volume of the hematoma was 20 to 50 mL (P0.004), or the Glasgow Coma Score was between
9 and 12 (P0.0009), or the patient was aged between 50 and 69 years (P0.01). In addition, there was some evidence
that more superficial hematomas with no intraventricular hemorrhage might also benefit (P0.09).
Conclusions—There is evidence that surgery is of benefit if undertaken early before the patient deteriorates. This work
identifies areas for further research. Ongoing studies in subgroups of patients such as the Surgical Trial in Lobar
Intracerebral Hemorrhage (STICH II) will confirm whether these interpretations can be replicated. (Stroke. 2012;43:
1496-1504.)
Key Words: intracerebral hemorrhage  meta-analysis  surgery
See related article, p 1460.
Spontaneous supratentorial intracerebral hemorrhage (ICH)has a high morbidity and mortality and places a significant
burden on health and social services. The role and timing of
operative neurosurgical intervention remain controversial and
the practice and timing of surgery continue to be haphazard.
Operative intervention is thought to be beneficial in stopping
bleeding, preventing rebleeding, and removing the mass effect to
prevent secondary brain damage. To date 14 trials have been
undertaken to investigate the role of surgery for spontaneous
ICH with varying conclusions (online-only Data Supplement, a
summary of trials). The first randomized trial was published in
1961 (McKissock1) and suggested that there was no significant
advantage for surgery. As the use of the CT scan in stroke
increased and operative techniques and care facilities improved,
more trials were undertaken with 4 small single-center trials
reported between 1989 and 1992.2–5 Further small studies
reported between 1998 and 2006,6–10 and 4 large studies were
published in 2001,11 2004,12 2005,13 and 2009.14 Few studies
have shown statistically significant differences and some
have favored surgery, whereas others have favored con-
servative treatment. The meta-analysis of the published
outcomes from these studies shows a significant benefit
from surgery both for the outcome of mortality15 and for
the combined outcome of death or disability (online-only
Supplemental Figures).16 However, there are many differ-
ences between the studies in the types of population
included and in the outcomes measured.
The aim of this study was to pool all available original data
from all trials of surgery versus conservative treatment in
spontaneous ICH to carry out an individual patient data
meta-analysis. Such pooled raw data make it possible to test
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subpopulations of patients with ICH and their response to
surgery. There were no raw data available from studies before
1985.
Methods
Study Selection and Data Items
The randomized controlled trials of surgery for ICH since CTs
became available were identified from the ongoing Cochrane Review
of Prasad et al.17 Presentation of the study design at conferences and
reviewing of relevant literature led to the identification of 2 further
articles: those of Pantazis et al10 and Wang et al.14 The authors of the
published articles were contacted by mail, e-mail, and at stroke and
neurosurgery conferences and were invited to take part in the study.
They were asked to describe the format of their data sets and indicate
which variables were available. Data requested included patient’s
age and sex, Glasgow Coma Score (GCS) at presentation, volume
and site of hematoma and presence of intraventricular hemorrhage
(IVH), method of evacuation of hematoma, time to randomization,
and outcome at 3 to 6 months.
Definition of Outcome
Different outcome measures were used by different studies. Glasgow
Outcome Scale had been used by 3 studies,3,7,13 whereas the
extended Glasgow Outcome Scale had only been used by Mende-
low.13 The Barthel Index was used by 3 studies,6,7,13 and the Rankin
Scale was the measure most commonly available in the data provided
by 6 studies.2,6–8,12,13 Batjer4 had used “independent at home” and
Hosseini9 had used Karnofsky. Chen11 had used a 5-category
variable based on the Barthel Index: death, vegetative state, Barthel
Index 60, Barthel Index 60, and excellent with no neurological
deficit.
The primary outcome for this analysis was defined as an unfavor-
able outcome. An unfavorable outcome was defined as death plus the
vegetative state or severe disability on the 5-point Glasgow Outcome
Scale. If this was not available, then a Rankin Scale score of3 was
considered as unfavorable; and if this was not available, an outcome
of Barthel Index of90 was considered unfavorable. An outcome of
moderate disability on the Glasgow Outcome Scale implies that an
individual is able to carry out shopping tasks and use public
transportation. Thus, a favorable outcome was regarded as being
independent outside the home. This differs from the prognosis-based
outcome derived from the extended Glasgow Outcome Scale that
was used in the Surgical Trial in Intracerebral Hemorrhage (STICH).13
The outcome classification from the Chen11 trial did not provide
sufficient information to code directly in this way so the classification of
“excellent” was the only category defined as a favorable outcome. These
decisions were made before the analysis of the data.
Prespecified Subgroup Analysis
For the analysis, each of the continuous baseline variables was
grouped. Categories were chosen to reflect the admission criteria in
the trials, previous publications, and criteria generally used in
making treatment decisions. Age was grouped into 3 categories:
50, 50 to 69, and 70 years. GCS was grouped into 3 groups: 3 to
8, 9 to 12, and 13 to 15; volume was classified into 4 groups: 20
mL, 20 to 50 mL, 50 to 80 mL, and 80 mL. These decisions were
made before the analysis of the data.
The data were analyzed using SPSS to crosstabulate the outcome
by treatment group for each baseline variable group and the values
entered into the Revman program to calculate the ORs and to
demonstrate the Forest plots.
Results
Study Selection
Numerous attempts were made to contact each first author by
mail and e-mail. Where this method was unsuccessful, further
attempts were made using third-party contacts made at confer-
ences or through other researchers and by holding meetings with
the trialists during conferences. This was a long process. Contact
was established with the authors of all studies. Hattori12 was
unable to take part. Batjer’s4 and Chen’s5 data were not retriev-
able. The main authors of each of the other contacted studies
agreed to be involved in this study and to provide data for it. Full
data sets have been supplied by Juvela, Morgenstern, Zuccarello,
Teernstra, Chen, Mendelow, and Wang.3,6–8,11,13,14 After an
exhaustive search in various universities taking 1 year, the
original data of Auer2 was not located but comprehensive tables
from a contemporary thesis analysis of the original data were
obtained.18 Hosseini9 supplied some aggregate data but of
insufficient detail to include in an individual patient data analy-
sis. In addition, the study has still not been published and
therefore not yet subjected to peer review. Pantazis10 supplied
full data for only 92 of his 108 cases. He was unable to locate the
data for the other 16 cases and therefore the decision was made
not to include these data in case it was a biased selection of the
cases.
Full data sets therefore have been supplied by 7 authors
(2086 patients) and grouped data by an eighth author (100
patients).
Table. Characteristics of Data Sets
Author Year
No. of
Cases
Male,
% Age, y GCS
Volume of
Hematoma, mL
Time to
Randomization, h
Lobar
Hematoma, %
IVH
Present, %
Favorable
Outcome,
% (Responders)
Auer 1989 100 NR 49%50 48%8 49%50 NR 45 32 25
Juvela 1989 52 58 51 (42–58) 24–65 12 (7–14) 4–15 58 (36–77) 17–152 NR 15 62 12
Morgenstern 1998 34 65 51 (43–63) 22–77 11 (10–14) 5–15 50 (30–76) 11–170 4 (1–6) 011 24 NR 19 (31)
Zuccarello 1999 20 55 64 (59–70) 27–80 12 (9–14) 4–15 33 (19–61) 16–105 7 (4–10) 2–19 50 50 45
Chen 2001 500 72 58 (49–65) 12–74 11 (9–13) 7–15 30 (22–45) 12–130 35%8 5 4 23
22%24
Teernstra 2003 70 57 70 (61–74) 46–87 9 (7–11) 4–15 59 (33–81) 10–132 4 (2–9) 0–62 54 31 11
Mendelow 2005 1033 57 62 (52–70) 19–93 12 (9–14) 5–15 38 (24–62) 4–210 20 (10–36) 2–72 35 39 18 (965)
Wang 2009 377 63 56 (50–65) 40–75 12 (10–14) 9–15 32 (28–37) 25–44 3 (2–8) 1–67 0 19 45
Median (quartiles), and minimum and maximum values of continuous variables. Percentage of categorical variables.
GCS indicates Glasgow Coma Score; IVH, intraventricular hemorrhage; NR, not recorded.
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Review: Trials of surgery for intracerebral haemorrhage (2012)
Comparison: 01 Location of haematoma                                                                                      
Outcome: 01 Unfavourable outcome                                                                                       
)dexif(RO)dexif(ROevitavresnoCyregruSydutS
IC%59IC%59N/nN/nyrogetac-busro
01 Lobar haematoma
 Auer       11/24              15/21      0.34 [0.10, 1.17]
 Juvela        4/5                0/3     21.00 [0.64, 689.99]
 Morgenstern        1/1                5/7      1.36 [0.04, 46.65]
 Zuccarello        3/5                2/5      2.25 [0.18, 28.25]
 Chen        7/11               9/13      0.78 [0.14, 4.27]
 Teernstra       22/24              11/14      3.00 [0.44, 20.67]
 Mendelow      121/181            146/195      0.68 [0.43, 1.06]
Subtotal (95% CI) 251                258      0.75 [0.52, 1.11]
Total events: 169 (Surgery), 188 (Conservative)
Test for heterogeneity: Chi² = 8.10, df = 6 (P = 0.23), I² = 26.0%
Test for overall effect: Z = 1.45 (P = 0.15)
02 Basal ganglia/thalamic haematomas
 Auer       23/26              26/29      0.88 [0.16, 4.82]
 Juvela       21/21              21/23      5.00 [0.23, 110.40]
 Morgenstern       12/14               7/9      1.71 [0.20, 15.02]
 Zuccarello        1/4                5/6      0.07 [0.00, 1.51]
 Chen      186/225            160/205      1.34 [0.83, 2.16]
 Teernstra       11/12              18/20      1.22 [0.10, 15.11]
 Mendelow      178/198            179/212      1.64 [0.91, 2.97]
 Wang       87/194            120/181      0.41 [0.27, 0.63]
Subtotal (95% CI) 694                685      0.84 [0.65, 1.10]
Total events: 519 (Surgery), 536 (Conservative)
Test for heterogeneity: Chi² = 23.93, df = 7 (P = 0.001), I² = 70.8%
Test for overall effect: Z = 1.27 (P = 0.20)
03 Additional intraventricular haemorrhage
 Auer       15/16              16/16      0.31 [0.01, 8.28]
 Juvela       19/20              12/12      0.52 [0.02, 13.80]
 Zuccarello        3/3                6/7      1.62 [0.05, 51.11]
 Chen        4/5                3/4      1.33 [0.06, 31.12]
 Teernstra        8/9               10/13      2.40 [0.21, 27.72]
 Mendelow      170/187            171/185      0.82 [0.39, 1.71]
 Wang       20/40              19/30      0.58 [0.22, 1.52]
Subtotal (95% CI) 280                267      0.77 [0.45, 1.31]
Total events: 239 (Surgery), 237 (Conservative)
Test for heterogeneity: Chi² = 1.83, df = 6 (P = 0.93), I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)
04 NO additional intraventricular haemorrhage
 Auer       19/34              25/34      0.46 [0.16, 1.26]
 Juvela        6/6                9/14      7.53 [0.35, 160.86]
 Zuccarello        1/6                1/4      0.60 [0.03, 13.58]
 Chen      189/231            166/214      1.30 [0.82, 2.07]
 Teernstra       23/25              18/20      1.28 [0.16, 9.97]
 Mendelow      181/246            213/280      0.88 [0.59, 1.30]
 Wang       67/154            101/151      0.38 [0.24, 0.61]
Subtotal (95% CI) 702                717      0.77 [0.61, 0.98]
Total events: 486 (Surgery), 533 (Conservative)
Test for heterogeneity: Chi² = 17.50, df = 6 (P = 0.008), I² = 65.7%
Test for overall effect: Z = 2.17 (P = 0.03)
05 Lobar haematomas with no IVH (assuming Auer IVH distributed evenly between treatment groups)
 Auer        8/21              12/18      0.31 [0.08, 1.15]
 Juvela        3/3                0/3     49.00 [0.74, 3236.99]
 Zuccarello        1/3                1/3      1.00 [0.03, 29.81]
 Chen        7/11               9/13      0.78 [0.14, 4.27]
 Teernstra       15/16               7/9      4.29 [0.33, 55.59]
 Mendelow       66/112             90/128      0.61 [0.36, 1.03]
Subtotal (95% CI) 166                174      0.68 [0.44, 1.06]
Total events: 100 (Surgery), 119 (Conservative)
Test for heterogeneity: Chi² = 7.63, df = 5 (P = 0.18), I² = 34.5%
Test for overall effect: Z = 1.69 (P = 0.09)
06 Basal ganglia/thalamic haematoma with no IVH
 Auer       11/13              13/16      1.27 [0.18, 9.02]
 Juvela        3/3                9/11      1.84 [0.07, 48.68]
 Zuccarello elbamitsetoN1/03/0
 Chen      182/220            157/202      1.37 [0.85, 2.22]
 Teernstra        8/9               11/11      0.25 [0.01, 6.82]
 Mendelow       89/101             88/113      2.11 [1.00, 4.45]
 Wang       67/154            101/151      0.38 [0.24, 0.61]
Subtotal (95% CI) 503                505      0.86 [0.64, 1.14]
Total events: 360 (Surgery), 379 (Conservative)
Test for heterogeneity: Chi² = 21.77, df = 5 (P = 0.0006), I² = 77.0%
Test for overall effect: Z = 1.06 (P = 0.29)
 0.1  0.2  0.5  1  2  5  10
 Favours surgery  Favours conservative
Figure 1. Meta-analysis by location of the hematoma.
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Study Characteristics
The Table summarizes the characteristics of the patients in
each of the trials. Only 1 data set contained details of the
depth of the hematoma from the cortical surface.13 This
would give an indication of the amount of healthy tissue that
has to be passed through to reach the clot. Seven studies had
recorded presence or absence of IVH but only 1 of these had
any measure of the severity of the IVH.13
Because only dichotomized data were obtained from Auer,
it is not always possible to include his data in the tables. He
categorized GCS as 3 to 8 and 9 to 15, age as 60 years or
60 years, and volume as 50 mL or 50 mL.
Location of Hematoma: Lobar or Deep and
Presence of IVH
All studies recorded location of hematoma. Outcome was
recorded for 509 patients with lobar hematoma (Figure 1).
The majority of the patients (376 [74%]) were from the
Mendelow et al trial and the overall OR was 0.75 (95% CI,
0.52–1.11; P0.15) showing a nonsignificant trend toward
surgery giving a favorable outcome. Outcome was recorded
for 1379 patients with basal ganglia or thalamic hematomas.
The studies of Chen, Mendelow, and Wang contribute most
patients to this analysis: 430, 410, and 375, respectively. The
OR was 0.84 (95% CI, 0.65–1.10) demonstrating no signifi-
cant difference (P0.20) in outcome according to whether
the patients were allocated to surgery or conservative treat-
ment. However, the test for heterogeneity demonstrates a
significant difference among these studies suggesting that the
results seen for the Wang study differ from those seen in the
other studies.
Seven studies recorded presence or absence of IVH. In
total, there were 1419 patients with no IVH: 526 from
Mendelow, 445 from Chen, and 305 from Wang. The OR was
0.77 (95% CI, 0.61–0.98; P0.03) indicating a significantly
more favorable outcome with surgery than with conservative
treatment when there was no IVH. There were 547 patients
with IVH, 373 being from the Mendelow trial. The OR was
similar at 0.77 (95% CI, 0.45–1.31), but there was no
evidence for an improvement in outcome from surgery for the
ICH when there was IVH due to the reduced power because
of a smaller sample size.
Further analysis was undertaken studying only those pa-
tients with lobar hematomas who did not have IVH. Full data
were available from 5 studies (301 cases) with incomplete
data from the fourth (Auer; 39 cases). From the reported
analyses we know that there were 6 patients who had lobar
hematomas and IVH in his data set and that 31 of 32 patients
with IVH had an unfavorable outcome. Thus, we can inves-
tigate a range of differences assuming all 6 patients were in
the conservative group or all 6 were in the surgical group or
there were 3 in each group. All these analyses give an OR
favoring surgery with significance levels varying between
P0.04 and P0.15. Assuming that the patients with IVH in
Review: Trials of surgery for intracerebral haemorrhage (2012)
Comparison: 05 Time from event                                                                                            
Outcome: 02 Unfavourable outcome                                                                                       
)dexif(RO)dexif(ROevitavresnoCyregruSydutS
IC%59IC%59N/nN/nyrogetac-busro
01 < 8 hrs
 Morgenstern       12/13              10/12      2.40 [0.19, 30.52]
 Zuccarello        4/7                3/4      0.44 [0.03, 6.70]
 Chen       97/123             75/90      0.75 [0.37, 1.51]
 Teernstra       20/23              23/27      1.16 [0.23, 5.81]
 Mendelow       80/87              75/86      1.68 [0.62, 4.55]
 Wang       66/144             95/136      0.37 [0.22, 0.60]
Subtotal (95% CI) 397                355      0.59 [0.42, 0.84]
Total events: 279 (Surgery), 281 (Conservative)
Test for heterogeneity: Chi² = 10.18, df = 5 (P = 0.07), I² = 50.9%
Test for overall effect: Z = 2.93 (P = 0.003)
02 8 <24 hrs
 Morgenstern        0/1                2/3      0.20 [0.00, 8.82]
 Zuccarello        0/2                4/7      0.16 [0.01, 4.40]
 Chen       69/90              59/80      1.17 [0.58, 2.35]
 Teernstra elbamitsetoN2/23/3
 Mendelow      134/158            167/197      1.00 [0.56, 1.80]
 Wang       12/30              13/22      0.46 [0.15, 1.42]
Subtotal (95% CI) 284                311      0.90 [0.60, 1.35]
Total events: 218 (Surgery), 247 (Conservative)
Test for heterogeneity: Chi² = 3.71, df = 4 (P = 0.45), I² = 0%
Test for overall effect: Z = 0.52 (P = 0.60)
03 24 < =72 hrs
 Chen       40/50              42/60      1.71 [0.71, 4.16]
 Teernstra        9/9                4/5      6.33 [0.21, 188.16]
 Mendelow      164/223            167/214      0.78 [0.50, 1.21]
 Wang        9/20              12/23      0.75 [0.23, 2.50]
Subtotal (95% CI) 302                302      0.93 [0.64, 1.34]
Total events: 222 (Surgery), 225 (Conservative)
Test for heterogeneity: Chi² = 3.77, df = 3 (P = 0.29), I² = 20.5%
Test for overall effect: Z = 0.41 (P = 0.68)
 0.1  0.2  0.5  1  2  5  10
 Favours surgery  Favours conservative
Figure 2. Meta-analysis by time of randomization.
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Auer’s data were equally distributed between the 2 groups
gives an OR 0.68 (95% CI, 0.44–1.06; P0.09).
Analysis of patients with a basal ganglia or thalamic
hematoma and no IVH had an OR of 0.86 (95% CI,
0.64–1.14; P0.29). There was a great deal of heterogeneity
in these data (P0.0006) with only the Wang and Teernstra
data demonstrating any tendency toward a favorable outcome
with surgery.
Time to Randomization
Two studies recruited patients in a 48-hour time window, but
the data were not recorded for individual patients.2,3 Time
was, therefore, only available for 6 studies and for 1 of the
studies, this had been recorded in a limited way as 8 hours,
8 to 24 hours, and 24 to 72 hours. Because of this lack of full
data, this categorization was therefore used for the analysis.
Approximately one third of the patients fell into each cate-
gorization (752 patients were randomized within 8 hours,
another 595 in 8–24 hours, and the other 604 in 24–72
hours). Only 4 studies included patients randomized 24
hours after ictus (Figure 2). These analyses suggested that
early operation (within 8 hours of ictus) was beneficial with
an OR of 0.59 (95% CI, 0.42–0.84; P0.003).
Age of the Patient
In total 444 patients were aged50 years and the Chen study
with one third of these patients had double the number in the
surgery group compared with the conservative group. The
studies tended to favor conservative rather than surgical
therapy (Figure 3) with the overall OR for patients50 years
being a nonsignificant 1.18 (95% CI, 0.78–1.78; P0.44).
Among the 1164 patients in the intermediate age group of 50
to 69 years, the OR was significantly in favor of surgery at
0.71 (95% CI, 0.54–0.94; P0.01), but again there was
evidence of heterogeneity. For the 396 patients aged 70
years, it was 0.82 (95% CI, 0.46–1.46; P0.51). In general,
older patients fared worse than younger patients; 85% of
patients aged 70 years had an unfavorable outcome com-
pared with 75% of those aged 50 to 69 years and 68% of
patients aged 50 years.
GCS at Randomization
There were 394 patients with a GCS of 3 to 8 (Figure 4). The
OR in favor of conservative treatment was 1.30 (95% CI,
0.49–3.48; P0.60). All studies showed no significant dif-
ference in outcome between surgery and conservative treat-
ment although tending to favor conservative treatment. Chen
showed imbalances in the allocation of patients in this GCS
Review: Trials of surgery for intracerebral haemorrhage (2012)
Comparison: 02 Age of patient                                                                                             
Outcome: 01 Unfavourable outcome                                                                                       
)dexif(RO)dexif(ROevitavresnoCyregruSydutS
IC%59IC%59N/nN/nyrogetac-busro
01 Age < 50
 Juvela       12/12               6/8      9.62 [0.40, 231.42]
 Morgenstern        6/7                4/5      1.50 [0.07, 31.57]
 Zuccarello elbamitsetoN2/01/0
 Chen       65/84              26/41      1.97 [0.87, 4.46]
 Teernstra elbamitsetoN1/11/1
 Mendelow       70/96              71/98      1.02 [0.54, 1.93]
 Wang       21/48              21/40      0.70 [0.30, 1.63]
Subtotal (95% CI) 249                195      1.18 [0.78, 1.78]
Total events: 175 (Surgery), 129 (Conservative)
Test for heterogeneity: Chi² = 4.86, df = 4 (P = 0.30), I² = 17.7%
Test for overall effect: Z = 0.77 (P = 0.44)
02 Age 50 - 69
 Juvela       13/14              15/18      2.60 [0.24, 28.15]
 Morgenstern        6/6                4/7     10.11 [0.41, 247.48]
 Zuccarello        2/6                4/5      0.13 [0.01, 2.00]
 Chen      124/161            131/167      0.92 [0.55, 1.55]
 Teernstra       17/18               9/11      3.78 [0.30, 47.56]
 Mendelow      197/247            216/263      0.86 [0.55, 1.33]
 Wang       54/120             85/121      0.35 [0.20, 0.59]
Subtotal (95% CI) 572                592      0.71 [0.54, 0.94]
Total events: 413 (Surgery), 464 (Conservative)
Test for heterogeneity: Chi² = 15.66, df = 6 (P = 0.02), I² = 61.7%
Test for overall effect: Z = 2.44 (P = 0.01)
03 Age >= 70
 Morgenstern        1/2                4/4      0.11 [0.00, 4.48]
 Zuccarello        2/2                3/4      2.14 [0.06, 77.54]
 Chen       17/18              19/22      2.68 [0.25, 28.31]
 Teernstra       15/16              18/21      2.50 [0.23, 26.60]
 Mendelow      111/125            122/136      0.91 [0.42, 1.99]
 Wang       12/26              14/20      0.37 [0.11, 1.25]
Subtotal (95% CI) 189                207      0.82 [0.46, 1.46]
Total events: 158 (Surgery), 180 (Conservative)
Test for heterogeneity: Chi² = 4.94, df = 5 (P = 0.42), I² = 0%
Test for overall effect: Z = 0.66 (P = 0.51)
 0.1  0.2  0.5  1  2  5  10
 Favours surgery  Favours conservative
Figure 3. Meta-analysis by age of the patient.
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range: 79 allocated to surgery and 28 to conservative
treatment.
There were 859 patients with a GCS between 9 and 12.
This group of patients demonstrated a significantly improved
outcome with surgery (OR, 0.54; 95% CI, 0.37–0.77;
P0.0009). All individual studies showed a tendency toward
improved outcome with surgery for this group of patients and
the test for heterogeneity was nonsignificant (P0.22).
There were 797 patients with a GCS between 13 and 15.
These patients also showed a significant difference in out-
come between surgery and initial conservative treatment (OR,
0.74; 95% CI, 0.55–0.99; P0.04).
In general, patients in a coma had a poorer outcome than
conscious patients: 95% of patients with a GCS 8 had an
unfavorable outcome compared with 81% of patients with a
GCS of 9 to 12, and 60% of patients with a GCS of 13 to 15.
Volume of Hematoma
There were 209 patients with a hematoma of 20 mL, 1233
with a hematoma of 20 to 49 mL, 373 with a hematoma of 50
to 79 mL, and 183 patients with a hematoma of80 mL. The
only category showing a significant treatment effect was the
group with the volume of between 20 and 49 mL (Figure 5).
The OR for this group was 0.69 (95% CI, 0.54–0.89;
P0.004). The smallest volume of hematomas (20 mL)
was the only category to show a tendency to favor conserva-
tive treatment. There is no evidence of a significant benefit
for surgery at other volumes. In general, larger volumes were
associated with worse outcomes: 93% of patients with a
hematoma of80 mL had an unfavorable outcome compared
with 69% of patients with a hematoma of 20 mL.
Discussion
Summary of Evidence
This study set out to obtain the raw data from as many of the
prospective randomized controlled trials of surgical treatment
for spontaneous supratentorial ICH as possible. This has
allowed exploration of clinically plausible hypotheses and
prespecified subgroup analysis ideas in larger data sets than
was available in the individual trials.
This study considered 1 intervention: removal of the clot
by physical means. This clot removal by surgery includes
craniotomy, aspiration, endoscopic aspiration, suction, and
catheter aspiration. The intervention has been explored in
terms of site, additional IVH, age of the patient, volume of
hematoma, GCS, and timing of the intervention.
Review: Trials of surgery for intracerebral haemorrhage (2012)
Comparison: 03 Glasgow Coma Score                                                                                         
Outcome: 01 Unfavourable outcome                                                                                       
)dexif(RO)dexif(ROevitavresnoCyregruSydutS
IC%59IC%59N/nN/nyrogetac-busro
01 GCS 3 - 8
 Auer       18/20              22/24      0.82 [0.10, 6.40]
 Juvela elbamitsetoN9/921/21
 Morgenstern elbamitsetoN3/32/2
 Zuccarello elbamitsetoN3/31/1
 Chen       74/79              27/28      0.55 [0.06, 4.91]
 Teernstra       13/13              11/12      3.52 [0.13, 95.09]
 Mendelow       86/88              95/100      2.26 [0.43, 11.97]
Subtotal (95% CI) 215                179      1.30 [0.49, 3.48]
Total events: 206 (Surgery), 170 (Conservative)
Test for heterogeneity: Chi² = 1.57, df = 3 (P = 0.67), I² = 0%
Test for overall effect: Z = 0.53 (P = 0.60)
02 GCS 9 - 12
 Juvela elbamitsetoN2/25/5
 Morgenstern        6/7                7/9      1.71 [0.12, 23.94]
 Zuccarello        1/2                3/5      0.67 [0.02, 18.06]
 Chen      101/122             81/89      0.48 [0.20, 1.13]
 Teernstra       14/17              12/14      0.78 [0.11, 5.46]
 Mendelow      163/187            173/196      0.90 [0.49, 1.66]
 Wang       61/118             67/86      0.30 [0.16, 0.57]
Subtotal (95% CI) 458                401      0.54 [0.37, 0.77]
Total events: 351 (Surgery), 345 (Conservative)
Test for heterogeneity: Chi² = 6.97, df = 5 (P = 0.22), I² = 28.3%
Test for overall effect: Z = 3.33 (P = 0.0009)
03 GCS 13 - 15
 Juvela        8/9               10/15      4.00 [0.39, 41.51]
 Morgenstern        5/6                2/4      5.00 [0.27, 91.52]
 Zuccarello        2/6                1/3      1.00 [0.05, 18.91]
 Chen       31/62              68/113      0.66 [0.35, 1.24]
 Teernstra        6/6                6/8      5.00 [0.20, 125.78]
 Mendelow      129/193            141/201      0.86 [0.56, 1.31]
 Wang       26/76              53/95      0.41 [0.22, 0.77]
Subtotal (95% CI) 358                439      0.74 [0.55, 0.99]
Total events: 207 (Surgery), 281 (Conservative)
Test for heterogeneity: Chi² = 9.01, df = 6 (P = 0.17), I² = 33.4%
Test for overall effect: Z = 2.03 (P = 0.04)
 0.1  0.2  0.5  1  2  5  10
 Favours surgery  Favours conservative
Figure 4. Meta-analysis by Glasgow Coma Score.
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The overall data have permitted us to re-evaluate the
prognostic features associated with ICH but it should be
remembered that the interventions of surgery may have
influenced these. Nevertheless, the well-known prognostic
factors are clearly evident in these data. A separate analysis of
the control arm of clinical trials of interventions (pharmaco-
logical and surgical) is underway and will be reported
separately. Advancing age, volume of clot, and level of
consciousness remain powerful predictors of outcome in this
data set.
The treatment of spontaneous supratentorial ICH has re-
mained and will remain controversial until a definitive
prospective randomized controlled trial comes up with firm
evidence in favor of a particular treatment. To date, both
medical and surgical trials have failed to do this. Traditional
treatment of ICH has been to observe the patient’s clinical
condition and to consider and offer surgery once the patient
deteriorates. This means that secondary brain damage has
taken place before the intervention of surgery. It would be
more logical to intervene before the onset of secondary brain
damage and this has been the theory behind many of the
surgical trials over the past 50 years. Other aspects of
intervention include prevention of expansion of the clot and
treatment of the source of bleeding. Medical therapies have
been aimed at these last 2 pathophysiological events but
surgery would deal with all 3. Analysis of trials to date has
suggested that there is a treatment effect but none has been
conclusive. Meta-analysis of these trials gives some indica-
tion as to the effectiveness but the different methods, treat-
ment intervals, outcome assessments, and methods of treat-
ment make comparison difficult. Future studies should aim to
standardize the collection of data. Actual measurements
Review: Trials of surgery for intracerebral haemorrhage (2012)
Comparison: 04 Volume of haematoma                                                                                        
Outcome: 01 Unfavourable outcome                                                                                       
)dexif(RO)dexif(ROevitavresnoCyregruSydutS
IC%59IC%59N/nN/nyrogetac-busro
01 Volume < 20 ml
 Juvela        1/1                1/2      3.00 [0.06, 151.19]
 Morgenstern        3/3                0/1     21.00 [0.27, 1646.18]
 Zuccarello        0/3                1/3      0.24 [0.01, 8.62]
 Chen        0/1                3/3      0.05 [0.00, 3.73]
 Teernstra        2/2                3/6      5.00 [0.17, 146.64]
 Mendelow       64/88              67/96      1.15 [0.61, 2.19]
Subtotal (95% CI) 98                 111      1.17 [0.66, 2.09]
Total events: 70 (Surgery), 75 (Conservative)
Test for heterogeneity: Chi² = 5.44, df = 5 (P = 0.36), I² = 8.1%
Test for overall effect: Z = 0.54 (P = 0.59)
02 Volume 20 - 50 ml
 Juvela        8/8                7/10      7.93 [0.35, 179.96]
 Morgenstern        4/5                4/6      2.00 [0.13, 31.98]
 Zuccarello        1/2                3/4      0.33 [0.01, 11.94]
 Chen      123/164            159/212      1.00 [0.62, 1.60]
 Teernstra        9/11              10/10      0.18 [0.01, 4.27]
 Mendelow      163/207            178/219      0.85 [0.53, 1.37]
 Wang       87/194            120/181      0.41 [0.27, 0.63]
Subtotal (95% CI) 591                642      0.69 [0.54, 0.89]
Total events: 395 (Surgery), 481 (Conservative)
Test for heterogeneity: Chi² = 12.68, df = 6 (P = 0.05), I² = 52.7%
Test for overall effect: Z = 2.88 (P = 0.004)
03 Volume 50 - 80 ml
 Juvela        9/10               9/9      0.33 [0.01, 9.26]
 Morgenstern        4/4                3/4      3.86 [0.12, 126.73]
 Zuccarello        1/2                2/3      0.50 [0.01, 19.56]
 Chen       66/78              12/13      0.46 [0.05, 3.86]
 Teernstra        7/8               12/12      0.20 [0.01, 5.57]
 Mendelow       96/111            102/119      1.07 [0.50, 2.25]
Subtotal (95% CI) 213                160      0.88 [0.47, 1.65]
Total events: 183 (Surgery), 140 (Conservative)
Test for heterogeneity: Chi² = 2.48, df = 5 (P = 0.78), I² = 0%
Test for overall effect: Z = 0.40 (P = 0.69)
04 Volume >= 80 ml
 Juvela        7/7                4/5      5.00 [0.17, 150.92]
 Morgenstern        2/3                5/5      0.15 [0.00, 5.18]
 Zuccarello elbamitsetoN1/12/2
 Chen       13/16               2/2      0.77 [0.03, 20.02]
 Teernstra       13/13               3/4     11.57 [0.38, 350.10]
 Mendelow       55/62              62/63      0.13 [0.02, 1.06]
Subtotal (95% CI) 103                80      0.56 [0.19, 1.60]
Total events: 92 (Surgery), 77 (Conservative)
Test for heterogeneity: Chi² = 7.06, df = 4 (P = 0.13), I² = 43.3%
Test for overall effect: Z = 1.09 (P = 0.28)
 0.1  0.2  0.5  1  2  5  10
 Favours surgery  Favours conservative
Figure 5. Meta-analysis by volume of the hematoma.
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should be recorded rather than grouped data such as the
grouped time to randomization recorded in the Chen study.11
All recognized predictive variables should be recorded and
outcome should be measured at 6 months as well as any
additional outcome points. Outcome should be measured
using the extended version of the Glasgow Outcome Scale as
well as modified Rankin Scale and other recognized assess-
ments of outcome.
Overall there is no evidence that hematomas located in the
deeper regions, basal ganglia or thalamus, may benefit from
surgery, although more recent studies using minimally inva-
sive techniques combined with clot lysis using urokinase
suggest that this may prove to be a fruitful area for further
research.14,19,20
There is, however, a suggestion that patients with lobar
hematomas and no IVH might benefit from surgery. Our
meta-analysis supports their selection as an appropriate pop-
ulation for the ongoing STICH II study.21
Our analysis confirms the benefits seen from surgery in the
Cochrane (second edition) Review.17 From this it has
emerged that the factors that are most likely to show benefit
with physical removal of the clot (that is different types of
surgery) are earlier intervention (timing), the treatment of
lobar and superficial hematomas, and the exclusion of pa-
tients with ventricular hemorrhage and/or hydrocephalus. The
question of early intervention has been the central theme of
the STICH trials and this is the first indication that early
surgery is beneficial. It would in fact be logical to hypothe-
size that the earlier the clot is removed, the better. However,
there have been studies that have suggested that ultraearly
surgery might lead to worse outcomes22 so further work is
needed. This will be a prespecified subgroup in STICH II.21
Limitations
Meta-analysis can be useful to identify trends and to set up
hypotheses for further trials. The results have to be inter-
preted with caution because of the different methods used in
each of the individual trials. Methods to evaluate studies that
use meta-analysis have been proposed, the most recent being
the Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) recommendations,23 which updates
the Quorum (Quality of reporting of Meta-analyses) state-
ment.24 The data that we have analyzed here are difficult to
report using these standards. In addition, Brand25has pointed
out the difficulty of conducting trials in a double-blind way in
the surgical arena.
Conclusions
Our data suggest that improved outcomes can be achieved
with early surgery within 8 hours of ictus, with hematomas of
20 to 50 mL, for patients with a GCS of 9 or for patients
aged 50 to 69 years. In particular, our analyses suggest that
when the GCS is 8, early surgery does not significantly
improve outcome. Taking this argument further suggests that
once the GCS has dropped to 8, then irretrievable damage
has already occurred and surgery will not be successful in
rescuing the patient.
This work has shown that the information available to date
does favor earlier surgical intervention in patients with ICH.
The ongoing studies STICH II, Minimally Invasive Surgery
Plus rtPA for ICH Evacuation (MISTIE), and Clot Lysis:
Evaluating Accelerated Resolution of Intraventricular Hem-
orrhage Phase III (CLEAR III) are focused on areas that this
analysis shows may offer promising results.19,21,26 Our work
also endorses the American Heart Association guidelines27
calling for more research to establish the groups that might
benefit from surgery. At present the recommendations for or
against surgery are based on conflicting evidence. These trials
should provide robust evidence on which to base future
recommendations.
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Individual patient data subgroup meta-analysis of surgery for spontaneous 
supratentorial intracerebral haemorrhage 
 
 
Table S1. Table of potential data sources 
 
Author 
(date of 
publication) 
Years of 
data 
collection 
No. of 
cases 
Evacuation 
method 
Time 
window 
Outcome 
measure 
Outcome 
timepoint 
Location of 
haematoma 
Other inclusion 
criteria 
McKissock 
(1961)
1 
1959-60 180 craniotomy >14 days Full work/ 
partial disability/ 
full disability/ 
dead 
6 months supratentorial  
Auer  
(1989)
2
 
1983-6 100 endoscopic 
evacuation 
48 hrs Similar to Rankin 6 months supratentorial Aged 30-80 
Volume >10ml 
Juvela  
(1989)
3
 
1982-6 52 craniotomy 48 hrs GOS 6 months supratentorial Aged <65  
 
Batjer  
(1990)
4
 
1987-9  21 craniotomy 24 hrs similar to GOS 6 months putaminal Aged 30-75 
Diameter > 3cm 
Chen  
(1992)
5
 
1986-90 127 craniectomy/ 
stereotaxy/ 
ventricular 
drainage 
Not 
recorded 
5 Category 
dead/worse/ 
moderate/ 
fair/good 
3 to 39 
months 
supratentorial  
cerebellar 
Not recorded 
Morgenstern 
(1998)
6
 
1993-6 34 craniotomy 12 hrs Barthel (Rankin) 6 months supratentorial GCS 5-15 
Volume >9ml 
Zuccarello 
(1999)
7
 
1994-6 20 craniotomy/ 
stereotaxy 
24 hrs GOS 3 months supratentorial Volume >10ml 
GCS >4 
Chen  
(2001)
8
 
1998 -
2000 
500 craniotomy/ 
burrhole (+/- 
streptokinase
/urokinase) 
72 hrs based on Barthel 3-6 
months 
supratentorial 
infratentorial 
Aged <70 
 GCS >6 
Volume >10ml 
Hossieni 
(2003)
9
 
Not 
recorded 
37 stereotactic 
aspiration  
24 hrs Karnofsky 12 
months 
“Deep” Aged >30 
Volume> 40ml 
Teernstra 
(2003)
10
 
1996-9 71 stereotactic 
aspiration + 
urokinase 
72 hrs Rankin 6 months supratentorial Aged >45 years 
Volume> 10ml 
Hattori 
(2004)
11
 
1998-
2000 
242 stereotactic 
evacuation 
24 hrs Rankin 12 
months 
putaminal Aged 35-85 
Japanese Coop 
Study grade 2-3 
Mendelow 
(2005)
12
 
1995-
2004 
1033 craniotomy/ 
other 
96 hrs GOS 
Rankin 
6 months supratentorial GCS>4 
Diameter > 2cm 
Pantazis 
(2006)
13
 
1998 - 
2003 
108 craniotomy 8 hrs GOS 12 
months 
supratentorial Volume > 30 ml 
Aged <80 
GCS <15 
Wang  
(2009)
14
 
2003-4 377 minimally 
invasive + 
urokinase 
72 hrs Rankin 3 months basal ganglia Aged 40-75 
GCS >8 
Volume 25-
40ml 
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Figure S1. Meta-analysis of published data for all 14 trials: Mortality 
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Figure S2. Meta-analysis of published data for death and disability 
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